Juan Valle, Chief Medical Officer at Cholangiocarcinoma Foundation, shared a post on LinkedIn:
“Join the Cholangiocarcinoma Foundation for this week’s Educational Webinar:
“Targeting Tomorrow: Two-agents, Three-targets with next generation immunotherapy (rilvegostomig) plus T-DXd for advanced HER2-expressing biliary tract cancers” Biliary tract cancers (BTCs) can be difficult to treat.
This webinar will share updates from the DESTINY-BTC01 trial, which is studying new combinations for patients with advanced or metastatic HER2-expressing BTC.
Presented by: Dr. Milind Javle, MD Anderson Cancer Center
Thursday, Sept. 25, 2025
4:00 PM (ET)
Register here.”
More posts featuring Juan W. Valle on OncoDaily.